I69.998 Insurance Policy Changes

ICD-10 I69.998 is officially defined as "Other sequelae following unspecified cerebrovascular disease." code I69.998 is referenced in 12 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I69.998 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 29, 2026Medium impact
Intra-coronary Hyperoxemic Therapy (CPB 0801, reviewed 2026-10-28)
Aetna's Clinical Policy Bulletin 0801 states that intra-coronary hyperoxemic therapy, also called aqueous oxygen therapy, is experimental, investigational or unproven for carbon monoxide poisoning, cardiogenic shock, radio-contrast nephropathy, reperfusion microvascular ischemia in persons with acute myocardial infarction, and stroke, because the evidence is insufficient. The policy lists ICD-10 codes as not covered for the indications listed in the policy, and says there are no specific CPT or HCPCS codes for hyperoxemic therapy.
Aetna · Identified Oct 23, 2026Medium impact
Actigraphy and Accelerometry (CPB 0710, reviewed 2026-10-15)
Aetna considers actigraphy testing (for example, Actiwatch) and accelerometry experimental, investigational, or unproven for listed uses, including diagnosing sleep disorders, diagnosing Alzheimer's disease, diagnosing hypertension, detecting seizures during sleep, and monitoring individuals with motor neuron diseases. CPT 95803 (actigraphy testing, minimum of 72 hours to 14 consecutive days of recording) and many listed ICD-10 codes, including those for depression, schizophrenia, Parkinson's disease and cerebral infarction, are not covered for the indications listed.
Aetna · Identified Oct 4, 2026Medium impact
Suit Therapy (CPB 0696, reviewed 2026-09-18)
Suit therapy, including the Adeli Suit, TheraTogs and other suit therapy devices, is considered experimental, investigational or unproven for cerebral palsy and other conditions, including gait rehabilitation following stroke. Dynamic movement orthoses are considered experimental, investigational or unproven for cerebral palsy, hemiparesis or hemiplegia, scoliosis and all other indications. The Dynamic Lycra Suit TLSO brace is considered experimental for cerebral palsy or scoliosis, and a TLSO is considered experimental for autism. The Benik vest or trunk support is considered experimental for individuals with low trunk tone and all other indications.
Aetna · Identified Aug 19, 2026Medium impact
Intermittent Pneumatic Compression Devices (CPB 0500, reviewed 2026-07-10)
Aetna considers full-leg or half-leg home-use pneumatic compression devices medically necessary durable medical equipment for chronic venous insufficiency of the legs in members with venous stasis ulcers that have failed to heal after a 6-month trial of conservative therapy directed by the treating physician. Intermittent pneumatic compression devices for the lower extremities are considered medically necessary for members who are bedridden due to trauma, orthopedic surgery, neurosurgery or other circumstances preventing ambulation, and a single patient use device is considered not medically necessary. Aetna lists other uses as experimental, investigational or unproven, including treatment of critical limb ischemia, intermittent claudication, post-thrombotic syndrome, restless legs syndrome and intra-operative compression for reduction of venous thromboembolism in craniotomy.
Aetna · Identified Aug 17, 2026Medium impact
Suit Therapy (CPB 0696, reviewed 2025-11-26)
Aetna considers suit therapy, including home use of suit therapy devices such as the Adeli Suit and TheraTogs, experimental, investigational, or unproven for members with cerebral palsy or other conditions, such as gait rehabilitation following stroke. Aetna also considers dynamic movement TLSO braces (Dynamic Lycra Suits) for cerebral palsy or scoliosis, Dynamic Movement Orthoses for cerebral palsy, hemiparesis or hemiplegia, scoliosis and all other indications, TLSO braces for autism, and the Benik vest for low trunk tone and all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)
Aetna considers quantitative EEG (brain mapping, also called BEAM) medically necessary only as an adjunct to traditional EEG for specified uses, including ambulatory EEG recording to facilitate later expert visual interpretation, continuous EEG monitoring by frequency-trending in the operating room or ICU, and topographic voltage and dipole analysis in pre-surgical evaluations for intractable epilepsy. Aetna considers quantitative EEG experimental, investigational or unproven for all other indications, including attention disorders, autism spectrum disorders, depression, schizophrenia, bipolar disorder, insomnia, fibromyalgia, post-traumatic stress disorder and post-concussion syndrome. The BrainScope One System (Ahead 300) is considered experimental, investigational or unproven for evaluation of concussion or traumatic brain injury.
Aetna · Identified Aug 15, 2026Medium impact
Carbogen Inhalation Therapy (CPB 0428, reviewed 2026-07-09)
Carbogen inhalation therapy (5% carbon dioxide and 95% oxygen) is considered experimental, investigational, or unproven for bladder cancer, central retinal artery occlusion, cervical cancer, fracture healing, head and neck cancers, optic nerve damage or degeneration, prostate cancer, retinal artery occlusion, seizures, stroke, and sudden hearing loss. The policy lists no specific CPT or HCPCS code for carbogen inhalation therapy, and the ICD-10 diagnosis codes for these indications are listed as not covered for carbogen inhalation therapy. The policy was last reviewed 07/09/2026.
Aetna · Identified Aug 14, 2026Medium impact
Chronic Vertigo (CPB 0238, reviewed 2026-04-23)
Aetna considers the Epley and Semont maneuvers medically necessary for benign paroxysmal positional vertigo only when a positive Hallpike test confirms the diagnosis and the member has had symptoms for at least 4 months, and considers them experimental for members with central nervous system disorders such as temporal lobe epilepsy, multiple sclerosis, cerebrovascular disease, or cerebellar lesions. Vestibular rehabilitation is medically necessary for chronic vertigo or persistent postural-perceptual dizziness when symptoms have lasted more than 6 months, a vestibular disorder is confirmed or ablative vestibular surgery was performed, and medical management has failed. Dynamic posturography, the Meniett device, the DizzyFix, the GyroStim machine, the Biodex BioSway, the BTrackS system, and posterior semicircular canal occlusion are listed as experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Phototherapy for Psychiatric Disorders (CPB 0370, reviewed 2026-05-26)
Aetna considers a high-intensity light unit for light box therapy medically necessary durable medical equipment for seasonal affective disorder only when the member has bipolar disorder or recurrent major depression and meets DSM-V criteria for a seasonal mood disorder. Those criteria are at least 2 years of seasonal depressive episodes that completely remit when daylight increases in the spring and that substantially outnumber any non-seasonal depressive episodes. When criteria are met, the first month of rental of the high-intensity light unit is covered to see whether home phototherapy relieves the member's depression. Light box therapy is experimental, investigational, or unproven for depressive symptoms in several other populations, including nonseasonal depression, perinatal depression, Parkinson disease, cystic fibrosis, type 2 diabetes, and dementia. Phototherapy for post-stroke depression is also listed as experimental.
Aetna · Identified Aug 12, 2026Medium impact
Biofeedback (CPB 0132, reviewed 2026-07-16)
Aetna considers biofeedback medically necessary for cancer pain, chronic constipation secondary to dyssynergic defecation as confirmed by anorectal manometry, fecal incontinence, irritable bowel syndrome, levator ani syndrome, migraine and tension headaches, refractory severe subjective tinnitus, temporomandibular joint syndrome, urinary incontinence, and neuromuscular rehabilitation of stroke and traumatic brain injury. Biofeedback is considered not medically necessary when used to improve emotional and physical health in non-diseased persons. EEG biofeedback is considered experimental, investigational, or unproven for migraine and tension headache, and several listed uses are experimental, including amygdala-related EEG neurofeedback for PTSD, HeartMath HRV biofeedback for headaches, InTandem for walking in chronic stroke, and surface EMG biofeedback for chronic ankle instability. Some Aetna plans exclude coverage of biofeedback.
Aetna · Identified Aug 12, 2026Medium impact
Actigraphy and Accelerometry (CPB 0710, reviewed 2025-10-14)
Aetna considers actigraphy testing experimental, investigational, or unproven for indications including defining lithium response dimensions in bipolar disorders, detection or screening of apnea, diagnosis of Alzheimer's disease, diagnosis of hypertension, evaluation of depression, and evaluation of schizophrenia. Aetna considers accelerometry experimental, investigational, or unproven for indications including evaluating functional ability in the elderly, differential diagnosis of tremor syndromes, gait analysis in persons with hip osteoarthritis, and monitoring of physical activity during rehabilitation of persons with stroke. CPT code 95803 (actigraphy testing, recording, analysis, interpretation and report, minimum of 72 hours to 14 consecutive days of recording) and CPT codes 0533T through 0536T (continuous recording of movement disorder symptoms) are not covered for the indications listed in the policy.
Aetna · Identified Aug 18, 2026Low impact
Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2025-11-24)
This is a historical copy of Aetna's clinical policy on thermal perfusion probes for monitoring regional cerebral blood flow (CPB 0703), last reviewed November 24, 2025 and first found by PolicyChanges in August 2026. Aetna treats the probe as experimental, investigational or unproven for acute neurological conditions, and the source gives no effective date.

Watch I69.998

Get one email when a payer policy names I69.998, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I69.998?

There are 12 tracked policy changes affecting code I69.998, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I69.998?

Payers that have issued tracked updates for code I69.998 include: Aetna.

How do I get notified when code I69.998 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I69.998. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I69.998?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Intra-coronary Hyperoxemic Therapy (CPB 0801, reviewed 2026-10-28)

Actigraphy and Accelerometry (CPB 0710, reviewed 2026-10-15)

Suit Therapy (CPB 0696, reviewed 2026-09-18)

Intermittent Pneumatic Compression Devices (CPB 0500, reviewed 2026-07-10)

Suit Therapy (CPB 0696, reviewed 2025-11-26)

Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)

Carbogen Inhalation Therapy (CPB 0428, reviewed 2026-07-09)

Chronic Vertigo (CPB 0238, reviewed 2026-04-23)

Phototherapy for Psychiatric Disorders (CPB 0370, reviewed 2026-05-26)

Biofeedback (CPB 0132, reviewed 2026-07-16)

Actigraphy and Accelerometry (CPB 0710, reviewed 2025-10-14)

Thermal Perfusion Probe for Monitoring Regional Cerebral Blood Flow (CPB 0703, reviewed 2025-11-24)

What insurance policy changes affect code I69.998?

Which payers have updated policy for code I69.998?

How do I get notified when code I69.998 policy changes?

Why do payers change policies for code I69.998?